Monkeypox Vaccine And Treatment Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends 2026-2030

The market comprises prophylactic vaccines and antiviral treatments targeting the mpox virus, a zoonotic orthopoxvirus. Current commercial offerings include Bavarian Nordic's Jynneos (also marketed as Imvanex in Europe), which received regulatory approval for mpox prevention, alongside antiviral treatments such as SIGA Technologies' Tpoxx (tecovirimat) and Chimerix's Tembexa (brincidofovir), which are used for treatment of confirmed cases. The market operates at a relatively small scale compared to broader infectious disease markets, reflecting the typically limited geographic spread of outbreaks.

• •Market valued at $0.113 billion in 2025 with 10.8% CAGR projected through the decade
• •Products span preventive vaccines and curative antiviral therapies
• •Regulatory approvals exist in North America and Europe for multiple treatment options

The primary growth catalyst stems from heightened global health surveillance following the 2022 multinational mpox outbreak, which demonstrated the potential for rapid international spread. Government and multilateral health organizations have established strategic stockpiles and accelerated procurement of vaccines and therapeutics, creating sustained demand. Additionally, ongoing research into next-generation vaccines and oral antiviral formulations promises to expand treatment accessibility in resource-limited settings.

• •Strategic national stockpiling by governments in North America, Europe, and parts of Asia-Pacific
• •Increased disease surveillance and diagnostic capacity improving case detection globally
• •Clinical trials advancing novel vaccine candidates, including mRNA-based platforms

Geographically, North America commands the largest market share due to comprehensive stockpiling programs and broad insurance coverage for approved products. Europe follows closely, with the European Medicines Agency's endorsement of Imvanex driving regional uptake. The Asia-Pacific region is emerging as a growth market, particularly in countries with historical mpox endemicity, though regulatory pathways and commercial access vary significantly across jurisdictions.

• •North America leads in revenue share, driven by US government procurement contracts
• •Europe represents a mature secondary market with established regulatory frameworks
• •Developing regions in Africa show potential growth as endemic countries improve healthcare infrastructure

What are the recent trends and outlook?

The market is moving toward broader geographic access and diversified product formats, including needle-free injection technologies and extended storage capabilities. Public health agencies are integrating mpox preparedness into broader emerging infectious disease response frameworks, suggesting sustained institutional demand beyond episodic outbreak cycles. Competition is expected to intensify as new vaccine candidates advance through clinical development, potentially driving price normalization and expanding indications to include pediatric and immunocompromised populations.

• •Next-generation vaccines in Phase 2 and Phase 3 clinical trials may enter market by 2027-2028
• •WHO prequalification efforts could accelerate access in low- and middle-income countries
• •Integrated preparedness strategies by Gavi and other health organizations may create bulk procurement opportunities